NGR014: Randomized Phase II Study of NGR-hTNF in Combination With Standard Chemotherapy Versus Standard Chemotherapy Alone in Previously Untreated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Trial Profile

NGR014: Randomized Phase II Study of NGR-hTNF in Combination With Standard Chemotherapy Versus Standard Chemotherapy Alone in Previously Untreated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs NGR-TNF (Primary) ; Cisplatin; Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors MolMed
  • Most Recent Events

    • 08 Oct 2015 Planned End Date changed from 1 Dec 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 17 Jun 2013 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2013 Final results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top